Beneficial Ownership Report · SCHEDULE 13G/A
Capricor Therapeutics, Inc.
CAPRNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Capricor Therapeutics, Inc.
- Company CIK
- 0001133869
- Street
- 10865 Road to the Cure
- Street (continued)
- Suite 150
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Statement details
- Amendment number
- 2
- Security class
- Common Stock, par value $0.001 per share
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- TANG CAPITAL MANAGEMENT, LLC
- Citizenship / organization
- DE
- Reporting person type
- OO
- Aggregate amount owned
- 0.00
- Percent of class
- 0
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
Reporting person 2
- Name
- KEVIN TANG
- Citizenship / organization
- X1
- Reporting person type
- IN
- Aggregate amount owned
- 0.00
- Percent of class
- 0
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
Reporting person 3
- Name
- TANG CAPITAL PARTNERS, LP
- Citizenship / organization
- DE
- Reporting person type
- PN
- Aggregate amount owned
- 0.00
- Percent of class
- 0
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
Reporting person 4
- Name
- TANG CAPITAL PARTNERS INTERNATIONAL, LP
- Citizenship / organization
- DE
- Reporting person type
- PN
- Aggregate amount owned
- 0.00
- Percent of class
- 0
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
Reporting person 5
- Name
- TANG CAPITAL PARTNERS III, INC
- Citizenship / organization
- NV
- Reporting person type
- CO
- Aggregate amount owned
- 0.00
- Percent of class
- 0
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
Reporting person 6
- Name
- TANG CAPITAL PARTNERS IV, INC
- Citizenship / organization
- NV
- Reporting person type
- CO
- Aggregate amount owned
- 0.00
- Percent of class
- 0
- Sole voting power
- 0.00
- Shared voting power
- 0.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 0.00
- Aggregate excludes certain shares
- N
Item 1
Issuer
Capricor Therapeutics, Inc.
Principal executive office address
10865 Road to the Cure, Suite 150, San Diego, CA, 92121
Item 2
Citizenship
TCM is a Delaware limited liability company. Mr. Tang is a United States citizen. TCP and TCPI is a Delaware limited partnership. TCP III and TCP IV are Nevada corporations that are indirectly wholly owned by TCP.
Filing person
This Statement on Schedule 13G (this "Statement") is filed by Tang Capital Management, LLC ("TCM"), the general partner of Tang Capital Partners, LP ("TCP") and Tang Capital Partners International, LP ("TCPI"); Kevin Tang, the manager of TCM and Chief Executive Officer of Tang Capital Partners III, Inc. ("TCP III") and Tang Capital Partners IV, Inc. ("TCP IV"); TCP; TCPI; TCP III; and TCP IV.
Principal business or residence address
The address of TCM, Kevin Tang and TCP is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 400 S. 4th Street, 3rd Floor, Las Vegas, NV 89101.
Item 3
Not applicable indication
Y
Item 4
Percent of class
0
Amount beneficially owned
0
Sole voting power
0 shares
Shared voting power
0 shares
Sole dispositive power
0 shares
Shared dispositive power
0 shares
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- TANG CAPITAL MANAGEMENT, LLC
- Signed
- /s/ Kevin Tang
- Title
- Manager
- Date
- 11/16/2026
Signature 2
- Reporting person
- KEVIN TANG
- Signed
- /s/ Kevin Tang
- Title
- Self
- Date
- 11/16/2026
Signature 3
- Reporting person
- TANG CAPITAL PARTNERS, LP
- Signed
- /s/ Kevin Tang
- Title
- Manager, Tang Capital Management, LLC, General Partner
- Date
- 11/16/2026
Signature 4
- Reporting person
- TANG CAPITAL PARTNERS INTERNATIONAL, LP
- Signed
- /s/ Kevin Tang
- Title
- Manager, Tang Capital Management, LLC, General
- Date
- 11/16/2026
Signature 5
- Reporting person
- TANG CAPITAL PARTNERS III, INC
- Signed
- /s/ Kevin Tang
- Title
- Chief Executive Officer
- Date
- 11/16/2026
Signature 6
- Reporting person
- TANG CAPITAL PARTNERS IV, INC
- Signed
- /s/ Kevin Tang
- Title
- Chief Executive Officer
- Date
- 11/16/2026
Company context
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for the treatment of Duchenne muscular dystrophy, evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and X.
Current securities
Historical securities (1)
Recent company filings
- 10-Q filingNov 10, 2026
- Results of Operations and Financial ConditionNov 10, 2026
- SCHEDULE 13G - filed by MILLENNIUM MANAGEMENT LLC regarding CAPRICOR THERAPEUTICS, INC.Sep 14, 2026
- Other EventsAug 24, 2026
- SCHEDULE 13G - filed by MILLENNIUM MANAGEMENT LLC regarding CAPRICOR THERAPEUTICS, INC.Aug 19, 2026